VIOLIN Logo
VO Banner
Search: for Help
About
Introduction
Statistics
VIOLIN News
Your VIOLIN
Register or Login
Submission
Tutorial
Vaccine & Components
Vaxquery
Vaxgen
VBLAST
Protegen
VirmugenDB
DNAVaxDB
CanVaxKB
Vaxjo
Vaxvec
Vevax
Huvax
Cov19VaxKB
Host Responses
VaximmutorDB
VIGET
Vaxafe
Vaxar
Vaxism
Vaccine Literature
VO-SciMiner
Litesearch
Vaxmesh
Vaxlert
Vaccine Design
Vaxign2
Vaxign
Community Efforts
Vaccine Ontology
ICoVax 2012
ICoVax 2013
Advisory Committee
Vaccine Society
Vaxperts
VaxPub
VaxCom
VaxLaw
VaxMedia
VaxMeet
VaxFund
VaxCareer
Data Exchange
V-Utilities
VIOLINML
Help & Documents
Publications
Documents
FAQs
Links
Acknowledgements
Disclaimer
Contact Us
UM Logo

Vaccine Detail

Infanrix
Vaccine Information
  • Vaccine Name: Infanrix
  • Target Pathogen: Corynebacterium diphtheriae
  • Target Disease: Diphtheria
  • Product Name: Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed
  • Tradename: Infanrix
  • Manufacturer: GlaxoSmithKline Biologicals
  • Vaccine Ontology ID: VO_0000064
  • CDC CVX code: 20
  • Type: Inactivated or "killed" vaccine
  • Status: Licensed
  • Location Licensed: USA (License #1617)
  • Host Species for Licensed Use: Human
  • Adjuvant:
    • Adjuvant name:
    • VO adjuvant ID: VO_0000127
    • Description: INFANRIX is indicated for active immunization against diphtheria, tetanus, and pertussis (whooping cough) as a 5-dose series in infants and children 6 weeks to 7 years of age. INFANRIX should not be administered to any infant before the age of 6 weeks, or to individuals 7 years of age or older (FDA: INFANRIX).
  • Preparation: The diphtheria toxin is produced by growing Corynebacterium diphtheriae in Fenton medium containing a bovine extract.
  • Immunization Route: Intramuscular injection (i.m.)
  • Storage: Store INFANRIX refrigerated between 2° and 8°C (36° and 46°F). Do not freeze.
  • Approved Age for Licensed Use: INFANRIX is indicated for active immunization against diphtheria, tetanus, and pertussis (whooping cough) as a 5-dose series in infants and children 6 weeks to 7 years of age (prior to seventh birthday). Because of the substantial risks of complications from pertussis disease in infants, completion of the primary series of 3 doses of vaccine early in life is strongly recommended. INFANRIX should not be administered to any infant before the age of 6 weeks, or to individuals 7 years of age or older. When passive protection against tetanus or diphtheria is required, Tetanus Immune Globulin or Diphtheria Antitoxin, respectively, should be administered at separate sites (FDA: INFANRIX).
  • Contraindication: Hypersensitivity to any component of the vaccine and ti should not be administered to anyone with a known previous allergic reaction associated with the vaccine (FDA: INFANRIX).
  • Description: INFANRIX is indicated for active immunization against diphtheria, tetanus, and pertussis (whooping cough) as a 5-dose series in infants and children 6 weeks to 7 years of age. INFANRIX should not be administered to any infant before the age of 6 weeks, or to individuals 7 years of age or older (FDA: INFANRIX).
Host Response

Human Response

  • Vaccination Protocol: Efficacy of diphtheria toxoid used in INFANRIX was determined on the basis of immunogenicity studies (FDA: INFANRIX).
  • Side Effects: Side effects of vaccination include: injection site reactions, fever, irritability, drowsiness, loss of appetite, and vomiting (FDA: INFANRIX).
  • Efficacy: A VERO cell toxin neutralizing test confirmed the ability of infant sera, obtained 1 month after a 3-dose primary series, to neutralize diphtheria toxin. Levels of diphtheria antitoxin were achieved in 100% of the sera tested (FDA: INFANRIX).
References
FDA: INFANRIX: FDA: INFANRIX [http://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm101568.htm]